QTTB Butterfly Strategy
QTTB (Q32 Bio Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
QTTB (Q32 Bio Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $457.5M, a trailing P/E of 9.25, a beta of -0.33 versus the broader market, a 52-week range of 1.62-23.57, average daily share volume of 1.2M, a public-listing history dating back to 2018, approximately 22 full-time employees. These structural characteristics shape how QTTB stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of -0.33 indicates QTTB has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. The trailing P/E of 9.25 is on the value side, where IV often compresses outside event windows because forward growth expectations are already discounted into the share price.
What is a butterfly on QTTB?
A long call butterfly buys one lower-strike call, sells two ATM calls, and buys one higher-strike call, paying a small net debit for a defined-risk position that maxes out if the underlying pins the middle strike at expiration.
QTTB snapshot
As of August 14, 2026, spot at $15.15, ATM IV 93.20%, IV rank 16.89%, expected move 26.72%. The butterfly on QTTB below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.
Why this butterfly structure on QTTB specifically: QTTB IV at 93.20% is on the cheap side of its 1-year range, which favors premium-buying structures like a QTTB butterfly, with a market-implied 1-standard-deviation move of approximately 26.72% (roughly $4.05 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated QTTB expiries trade a higher absolute premium for lower per-day decay. Position sizing on QTTB should anchor to the underlying notional of $15.15 per share and to the trader's directional view on QTTB stock.
QTTB butterfly setup
The QTTB butterfly below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With QTTB at $15.15 on that close, the first option leg uses a $14.39 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed QTTB chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 QTTB shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $14.39 | N/A |
| Sell 2 | Call | $15.15 | N/A |
| Buy 1 | Call | $15.91 | N/A |
QTTB butterfly risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals the wing width minus net debit times 100 (reached when the underlying pins the middle strike); max loss equals the net debit times 100. Two breakevens at lower-wing plus debit and upper-wing minus debit.
QTTB butterfly payoff curve
Modeled P&L at expiration across a range of underlying prices for the butterfly on QTTB. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use butterfly on QTTB
Butterflies on QTTB are pinning bets - traders use them when they expect QTTB to settle near a specific level at expiration (often the prior close, a round number, or the max-pain strike) and want defined-risk exposure to that outcome.
QTTB thesis for this butterfly
The market-implied 1-standard-deviation range for QTTB extends from approximately $11.10 on the downside to $19.20 on the upside. A QTTB long call butterfly is a pinning play: it pays maximum at the middle strike if QTTB settles there at expiration, with the wing legs capping both the cost and the maximum loss to the net debit. Current QTTB IV rank near 16.89% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on QTTB at 93.20%. As a Healthcare name, QTTB options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to QTTB-specific events.
QTTB butterfly positions are structurally neutral / pin (limited-risk, limited-reward); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. QTTB positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move QTTB alongside the broader basket even when QTTB-specific fundamentals are unchanged. Always rebuild the position from current QTTB chain quotes before placing a trade.
Frequently asked questions
- What is a butterfly on QTTB?
- A butterfly on QTTB is the butterfly strategy applied to QTTB (stock). The strategy is structurally neutral / pin (limited-risk, limited-reward): A long call butterfly buys one lower-strike call, sells two ATM calls, and buys one higher-strike call, paying a small net debit for a defined-risk position that maxes out if the underlying pins the middle strike at expiration. With QTTB stock at $15.15 on the most recent close, the strikes shown on this page are snapped to the nearest listed QTTB chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are QTTB butterfly max profit and max loss calculated?
- Max profit equals the wing width minus net debit times 100 (reached when the underlying pins the middle strike); max loss equals the net debit times 100. Two breakevens at lower-wing plus debit and upper-wing minus debit. For the QTTB butterfly priced from the end-of-day chain at a 30-day expiry (ATM IV 93.20%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a QTTB butterfly?
- The breakeven for the QTTB butterfly priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The QTTB market-implied 1-standard-deviation expected move in the same options snapshot is approximately 26.72%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a butterfly on QTTB?
- Butterflies on QTTB are pinning bets - traders use them when they expect QTTB to settle near a specific level at expiration (often the prior close, a round number, or the max-pain strike) and want defined-risk exposure to that outcome.
- How does current QTTB implied volatility affect this butterfly?
- QTTB ATM IV is at 93.20% with IV rank near 16.89%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.